| 发明名称 |
Use of PEGylated IGF-I Variants For The Treatment Of Neuromuscular Disorders |
| 摘要 |
The present invention relates to a pharmaceutical composition containing a PEGylated IGF-I variant derived from the wild-type human IGF-I amino acid sequence where one or two of the lysine amino acids at positions 27, 65, and 68 are altered to be a polar amino acid other than lysine and where the PEG is attached to at least one lysine residue. The invention also relates to methods for the treatment, prevention and/or delay of progression of neuromuscular disorders, in particular amyotrophic lateral sclerosis (ALS) by administering a therapeutically effective amount of the pharmaceutical composition of the invention. |
| 申请公布号 |
US2015273023(A1) |
申请公布日期 |
2015.10.01 |
| 申请号 |
US201514684772 |
申请日期 |
2015.04.13 |
| 申请人 |
Hoffmann-La Roche Inc. |
发明人 |
Holtmann Bettina;Metzger Friedrich;Sendtner Michael |
| 分类号 |
A61K38/30;A61K47/48 |
主分类号 |
A61K38/30 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method for the treatment of neuromuscular disorders comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition wherein the composition comprises a PEGylated IGF-I variant derived from the wild-type human IGF-I amino acid sequence (SEQ ID NO:1) wherein one or two of the lysine amino acids at positions 27, 65, and 68 are altered to be a polar amino acid other than lysine and wherein the polyethylene glycol (PEG) is attached to at least one lysine and a pharmaceutically acceptable carrier. |
| 地址 |
Nutley NJ US |
